Related Experiment Video
Updated: Jan 29, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
Avasimibe inhibits tumor growth by targeting FoxM1-AKR1C1 in osteosarcoma
Liang Wang1, Yang Liu1, Guanzhen Yu2
1Department of Orthopedic, Changzheng Hospital, Shanghai 200003, China.
Background:
Osteosarcoma (OS) is a rare bone tumor with a high propensity for lung metastasis and poor patient outcomes. It is crucial to identify novel therapeutic strategies and biomarkers.
Patients And Methods:
ARK1C1 staining was detected in OS specimens, and its clinical significance was assessed. A potential AKR1C1 inhibitor, avasimibe, was used to target AKR1C1.
Results:
High expression of AKR1C1 was observed in OS and was associated with poor outcomes for patients with OS. Avasimibe was found to inhibit cell proliferation and tumor growth by reducing the expression of AKR1C1 and FoxM1 in vivo and in vitro.
Conclusion:
These findings indicate that AKR1C1 is a promising prognostic factor and may serve as a novel therapeutic target of avasimibe for human OS.
Insights
High AKR1C1 expression in osteosarcoma (OS) correlates with poor outcomes. Targeting AKR1C1 with avasimibe shows promise for treating this bone cancer by inhibiting tumor growth.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Osteosarcoma (OS) is a rare bone cancer characterized by high rates of lung metastasis and poor patient prognosis.
- Identifying novel therapeutic targets and prognostic biomarkers is critical for improving outcomes in OS patients.
Purpose of the Study:
- To investigate the role of Aldo-keto Reductase Family 1 Member C1 (AKR1C1) as a prognostic factor in osteosarcoma.
- To evaluate the therapeutic potential of avasimibe, an AKR1C1 inhibitor, in osteosarcoma treatment.
Main Methods:
- AKR1C1 protein expression levels were assessed in osteosarcoma specimens.
- The clinical significance of AKR1C1 expression was correlated with patient outcomes.
- In vitro and in vivo studies were conducted using avasimibe to target AKR1C1 in osteosarcoma models.
Main Results:
- Elevated AKR1C1 expression was significantly observed in osteosarcoma tissues.
- High AKR1C1 expression was associated with poorer clinical outcomes in patients with osteosarcoma.
- Avasimibe treatment effectively inhibited osteosarcoma cell proliferation and tumor growth, accompanied by reduced expression of AKR1C1 and FoxM1.
Conclusions:
- AKR1C1 serves as a potential prognostic biomarker for osteosarcoma.
- Targeting AKR1C1 with avasimibe represents a promising novel therapeutic strategy for human osteosarcoma.
Related Concept Videos
Feedback Inhibition
Enzyme Inhibition
Population Growth
Primary and Secondary Growth in Roots and Shoots
Inhibition of Cdk Activity
Meristems and Plant Growth

